# CorMedix Inc.: overview

CRMD · Nasdaq · CIK 1410098 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crmd.md) · [Financials](/companies/crmd/financials.md) · [Filings](/companies/crmd/filings.md) · [Insiders](/companies/crmd/insiders.md)

Latest reported revenue: [$101.9m](/filings/0001410098-26-000056.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001410098-26-000056).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.5](/filings/0001213900-25-108777.md) | [31.2 d](/filings/0001213900-26-023889.md) | [39.1](/filings/0001410098-26-000021.md) | [39.7](/filings/0001410098-26-000056.md) | [104](/filings/0001213900-25-108777.md) | [129 d](/filings/0001213900-26-023889.md) | [127](/filings/0001410098-26-000021.md) | [102](/filings/0001410098-26-000056.md) |
| Gross margin | % | [94.0%](/filings/0001213900-25-108777.md) | [96.2% d](/filings/0001213900-26-023889.md) | [95.9%](/filings/0001410098-26-000021.md) | [95.3%](/filings/0001410098-26-000056.md) | [89.3%](/filings/0001213900-25-108777.md) | [83.4% d](/filings/0001213900-26-023889.md) | [82.5%](/filings/0001410098-26-000021.md) | [75.7%](/filings/0001410098-26-000056.md) |
| Operating margin | % | [(28.7%)](/filings/0001213900-25-108777.md) | [41.4% d](/filings/0001213900-26-023889.md) | [51.5%](/filings/0001410098-26-000021.md) | [49.2%](/filings/0001410098-26-000056.md) | [49.2%](/filings/0001213900-25-108777.md) | [46.0% d](/filings/0001213900-26-023889.md) | [50.0%](/filings/0001410098-26-000021.md) | [42.1%](/filings/0001410098-26-000056.md) |
| Net margin | % | [(24.2%)](/filings/0001213900-25-108777.md) | [43.1% d](/filings/0001213900-26-023889.md) | [52.8%](/filings/0001410098-26-000021.md) | [49.9%](/filings/0001410098-26-000056.md) | [104.1%](/filings/0001213900-25-108777.md) | [10.9% d](/filings/0001213900-26-023889.md) | [30.3%](/filings/0001410098-26-000021.md) | [25.5%](/filings/0001410098-26-000056.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001213900-25-108777.md) | not reported | [0.30](/filings/0001410098-26-000021.md) | [0.28](/filings/0001410098-26-000056.md) | [1.26](/filings/0001213900-25-108777.md) | not reported | [0.43](/filings/0001410098-26-000021.md) | [0.29](/filings/0001410098-26-000056.md) |
| Free cash flow | $m | [(13.7) d](/filings/0001213900-25-108777.md) | [(5.6) d](/filings/0001213900-26-023889.md) | [19.7](/filings/0001410098-26-000021.md) | [30.0 d](/filings/0001410098-26-000056.md) | [30.4 d](/filings/0001213900-25-108777.md) | [92.7 d](/filings/0001213900-26-023889.md) | [41.7](/filings/0001410098-26-000021.md) | [85.7 d](/filings/0001410098-26-000056.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001213900-23-024310.md) | [0.1](/filings/0001213900-24-021585.md) | not reported | [43.5](/filings/0001213900-26-023889.md) | [312](/filings/0001213900-26-023889.md) |
| Gross margin | % | [22.0%](/filings/0001213900-23-024310.md) | [94.3%](/filings/0001213900-24-021585.md) | not reported | [92.7%](/filings/0001213900-26-023889.md) | [88.5%](/filings/0001213900-26-023889.md) |
| Operating margin | % | [(15417.5%)](/filings/0001213900-23-024310.md) | [(46819.9%)](/filings/0001213900-24-021585.md) | not reported | [(51.4%)](/filings/0001213900-26-023889.md) | [48.2%](/filings/0001213900-26-023889.md) |
| Net margin | % | [(14774.7%)](/filings/0001213900-23-024310.md) | [(45409.9%)](/filings/0001213900-24-021585.md) | not reported | [(41.2%)](/filings/0001213900-26-023889.md) | [52.3%](/filings/0001213900-26-023889.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0001213900-23-024310.md) | [(0.74)](/filings/0001213900-24-021585.md) | [(0.91)](/filings/0001013762-25-001852.md) | [(0.30)](/filings/0001213900-26-023889.md) | [2.04](/filings/0001213900-26-023889.md) |
| Free cash flow | $m | [(22.6)](/filings/0001213900-23-024310.md) | [(24.6)](/filings/0001213900-24-021585.md) | [(38.7)](/filings/0001013762-25-001852.md) | [(50.7)](/filings/0001213900-26-023889.md) | [173](/filings/0001213900-26-023889.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $49.6m | 6,324,111 |  | Added +356,536 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $49.3m | 6,274,076 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $24.6m | 3,135,075 |  | Added +5,419 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $18.2m | 2,316,845 |  | Added +125,002 |
| [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $17.1m | 2,176,362 |  | Added +288,830 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $15.3m | 1,947,014 |  | Added +130,107 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $14.7m | 1,877,940 |  | Added +339,695 |
| [OBERWEIS ASSET MANAGEMENT INC/](/funds/937886.md) | 2026-06-30 | $10.4m | 1,323,915 |  | Added +112,800 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $6.7m | 850,000 |  | Unchanged |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $6.1m | 779,535 |  | Added +276,570 |

## Recent filings

[All 1,125 filings](/companies/crmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 12:00 ET | [8-K](/filings/0001213900-26-110477.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-110477 |
| 2026-08-13 | 12:07 ET | [10-Q](/filings/0001410098-26-000056.md) | Quarterly report, period 2026-06-30 | 0001410098-26-000056 |
| 2026-08-13 | 11:32 ET | [8-K](/filings/0001410098-26-000054.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001410098-26-000054 |
| 2026-08-07 | 20:18 ET | [8-K](/filings/0001410098-26-000044.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001410098-26-000044 |
| 2026-07-02 | 20:30 ET | [8-K](/filings/0001410098-26-000040.md) | 8.01 Other events | 0001410098-26-000040 |
| 2026-07-01 | 11:14 ET | [8-K](/filings/0001410098-26-000037.md) | 4.01 Change of auditor | 0001410098-26-000037 |
| 2026-06-24 | 20:30 ET | [8-K](/filings/0001410098-26-000028.md) | 5.07 Shareholder vote results | 0001410098-26-000028 |
| 2026-06-08 | 12:45 ET | [8-K](/filings/0001213900-26-066061.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-066061 |
| 2026-05-14 | 12:00 ET | [10-Q](/filings/0001410098-26-000021.md) | Quarterly report, period 2026-03-31 | 0001410098-26-000021 |
| 2026-05-14 | 11:34 ET | [8-K](/filings/0001410098-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001410098-26-000020 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-023889.md), filed Mar 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1b49e90d-abce-4df6-b9cd-864a72190a8f)

## About the filer

- CIK: 1410098
- Tickers: CRMD
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.